UBE Microdiscectomy Beneficial for Lumbar Disc Herniation
By Elana Gotkine HealthDay Reporter
TUESDAY, Sept. 24, 2024 -- For adults with symptomatic lumbar disc herniation, unilateral biportal endoscopic (UBE) microdiscectomy is associated with longer operating times and with lower pain medication consumption in the early postoperative period compared with tubular lumbar microdiscectomy, according to a study published online Sept. 19 in Blood.
Charla Fischer, M.D., from NYU Langone Health in New York City, and colleagues examined surgical outcomes and pain medication consumption for UBE versus tubular lumbar microdiscectomy in a retrospective cohort study of adults undergoing primary, single-level UBE or tubular lumbar microdiscectomy surgery at a high-volume institution. Data were included for 102 patients: 48 undergoing UBE and 54 tubular lumbar microdiscectomy.
The researchers found that the average operative time was higher for UBE than for tubular patients (133.1 versus 86.6 minutes), which trended downward over time but did not reach statistical significance. Complication or reoperation rates did not differ. From discharge to two-week follow-up, the average daily morphine milligram equivalents were lower in the UBE group (11.1 versus 14.1) but were similar thereafter. The UBE cohort had lower nonopioid medication prescription from discharge to two weeks (70.8 versus 92.6 percent) and two to six weeks (52.1 versus 85.2 percent), with no significant differences seen thereafter.
"This breakthrough technique is a game changer because it gives patients a better recovery with less pain and less need for narcotics and their related side-effects," Fischer said in a statement.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
ASCO: Durvalumab Plus FLOT Beneficial for Resectable Gastric, GE Junction Cancer
THURSDAY, June 5, 2025 -- For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel...
Endolymphatic Sac Decompression Effective for Vertigo, Migraine
WEDNESDAY, May 28, 2025 -- For Meniere disease (MD) patients with migraine, endolymphatic sac decompression (ELSD) is effective, providing postoperative relief of vertigo and...
One-Week Radiotherapy for Breast Cancer Safe, Effective Up to 10 Years
TUESDAY, May 27, 2025 -- A five-fraction, one-week schedule of adjuvant breast radiotherapy is as safe and effective as a standard three-week schedule for patients with invasive...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.